86,000 Shares of Compass Pathways PLC Sponsored ADR $CMPS Purchased by Maxi Investments CY Ltd

Maxi Investments CY Ltd acquired a new stake in shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 86,000 shares of the company’s stock, valued at approximately $1,070,000. Maxi Investments CY Ltd owned about 0.06% of Compass Pathways as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in CMPS. EverSource Wealth Advisors LLC lifted its holdings in shares of Compass Pathways by 67.7% during the first quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after purchasing an additional 1,920 shares during the period. WINTON GROUP Ltd increased its stake in Compass Pathways by 20.1% in the 2nd quarter. WINTON GROUP Ltd now owns 17,900 shares of the company’s stock valued at $253,000 after buying an additional 3,000 shares during the period. Ancora Advisors LLC acquired a new position in Compass Pathways in the 2nd quarter valued at $43,000. TD Waterhouse Canada Inc. raised its position in Compass Pathways by 10.9% during the 3rd quarter. TD Waterhouse Canada Inc. now owns 33,622 shares of the company’s stock worth $401,000 after buying an additional 3,316 shares during the last quarter. Finally, North Star Investment Management Corp. raised its position in Compass Pathways by 1,354.0% during the 1st quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock worth $42,000 after buying an additional 7,000 shares during the last quarter. 46.19% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on CMPS shares. Wells Fargo & Company initiated coverage on shares of Compass Pathways in a report on Monday, July 27th. They issued an “equal weight” rating and a $13.00 target price on the stock. Wall Street Zen upgraded shares of Compass Pathways from a “strong sell” rating to a “sell” rating in a research note on Tuesday, September 1st. Stifel Nicolaus increased their price target on shares of Compass Pathways from $14.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. BTIG Research increased their price target on shares of Compass Pathways from $14.00 to $25.00 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Finally, Evercore upgraded shares of Compass Pathways from an “in-line” rating to an “outperform” rating and set a $21.00 price objective for the company in a research report on Wednesday, July 8th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $23.36.

Compass Pathways Price Performance

Shares of NASDAQ:CMPS opened at $11.05 on Tuesday. The business’s 50 day simple moving average is $13.06 and its 200-day simple moving average is $10.29. The firm has a market capitalization of $1.53 billion, a price-to-earnings ratio of -2.39 and a beta of 2.55. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.30 and a quick ratio of 1.30. Compass Pathways PLC Sponsored ADR has a 12 month low of $4.88 and a 12 month high of $15.87.

Compass Pathways (NASDAQ:CMPS) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($1.49). As a group, equities analysts forecast that Compass Pathways PLC Sponsored ADR will post -1.26 earnings per share for the current fiscal year.

Compass Pathways Profile

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.